New Chinese Consensus Guidelines Standardize Precision Treatment for Pediatric Low-Grade Gliomas

New 2024 Chinese consensus guidelines for pediatric low-grade gliomas focus on molecular diagnostics and age-appropriate neuro-oncology treatments.

By: AXL Media

Published: Apr 21, 2026, 9:51 AM EDT

Source: Information for this report was sourced from EurekAlert!

Establishing a Specialized Framework for Pediatric Neuro-Oncology

Pediatric low-grade gliomas (pLGGs) represent approximately 25% to 40% of all central nervous system tumors in children, requiring a biological approach distinct from adult cases. To address this, a multidisciplinary panel of experts has developed the 2024 Chinese consensus guidelines, recently published in the journal Neurosurgical Subspecialties. With an estimated annual incidence in China of 0.53 to 0.65 per 100,000 children, the guidelines aim to standardize care across the nation. By prioritizing molecular-integrated diagnosis, the framework ensures that clinical decisions are based on the specific genetic drivers of the tumor rather than just histological appearance.

Advancing Diagnostic Precision through Multimodal Imaging

The guidelines identify MRI as the essential tool for initial assessment and long-term monitoring, recommending a suite of sequences including T1WI, T2WI, and FLAIR. For a more nuanced understanding of tumor behavior, the panel suggests the use of multimodal sequences such as diffusion-weighted imaging (DWI) and magnetic resonance spectroscopy (MRS) when available. Postoperative assessments are now strictly mandated within 72 hours of surgery to accurately determine the extent of resection. Furthermore, the guidelines adopt the RAPNO 2020 criteria for response assessment, providing clinicians with clear metrics to define radiological progression in both solid and cystic tumor components.

Surgical Objectives and the Role of Molecular Profiling

Gross total resection remains the primary predictor of long-term survival, with 10-year overall survival rates reaching up to 90% in successfully cleared cases. For tumors located in high-risk areas like the optic pathway or brainstem, the guidelines advocate for multidisciplinary discussions to balance tumor debulking with functional preservation. Parallel to surgical intervention, comprehensive molecular profiling is now highly recommended. Since pLGGs are typically driven by alterations in the RAS/MAPK pathway, identifying specific markers such as BRAF fusions or V600E mutations is critical for selecting the appropriate targeted therapies.